- Home
- GITS vs GLMD Comparison
GITS vs GLMD Comparison
Compare GITS & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- GLMD
- Stock Information
- Founded
- GITS 2018
- GLMD 2000
- Country
- GITS South Korea
- GLMD Israel
- Employees
- GITS N/A
- GLMD N/A
- Industry
- GITS
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- GLMD Health Care
- Exchange
- GITS Nasdaq
- GLMD Nasdaq
- Market Cap
- GITS 7.0M
- GLMD 7.5M
- IPO Year
- GITS N/A
- GLMD 2014
- Fundamental
- Price
- GITS $2.51
- GLMD $1.48
- Analyst Decision
- GITS
- GLMD Hold
- Analyst Count
- GITS 0
- GLMD 1
- Target Price
- GITS N/A
- GLMD N/A
- AVG Volume (30 Days)
- GITS 22.9K
- GLMD 213.6K
- Earning Date
- GITS 08-15-2025
- GLMD 11-13-2025
- Dividend Yield
- GITS N/A
- GLMD N/A
- EPS Growth
- GITS N/A
- GLMD N/A
- EPS
- GITS N/A
- GLMD N/A
- Revenue
- GITS $29.00
- GLMD N/A
- Revenue This Year
- GITS N/A
- GLMD N/A
- Revenue Next Year
- GITS N/A
- GLMD N/A
- P/E Ratio
- GITS N/A
- GLMD N/A
- Revenue Growth
- GITS N/A
- GLMD N/A
- 52 Week Low
- GITS $0.87
- GLMD $1.15
- 52 Week High
- GITS $9.78
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- GITS 53.01
- GLMD 51.13
- Support Level
- GITS N/A
- GLMD $1.33
- Resistance Level
- GITS $2.74
- GLMD $1.60
- Average True Range (ATR)
- GITS 0.17
- GLMD 0.10
- MACD
- GITS -0.05
- GLMD 0.03
- Stochastic Oscillator
- GITS 91.61
- GLMD 66.67
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.